Entity: Department of Health and Human Services (DHHS)
Body: Pharmacy and Therapeutics Committee
| Notice Title: | State Medicaid Pharmacy & Therapeutics Committee Meeting |
| Notice Tags: | Medicaid, Pharmacies |
| Meeting Location: | 288 North 1460 West Cannon Health Building, Room 114 Salt Lake City 84116 |
| Event Date & Time: |
December 15, 2011 December 15, 2011 07:00 AM - December 15, 2011 08:30 AM |
| Description/Agenda: |
UTAH DEPARTMENT OF HEALTH
STATE MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE
Thursday, December 15, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114
AGENDA
Please note that persons who wish to address the P&T Committee may contact Lisa V. Hunt (lvhunt@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints
1. Welcome and Introductions..................................................Chair, Ellie Brownstein, M.D.
a. Review and Approval of Minutes
2. Update on PDL Administration…………...............................................Lisa V. Hunt, R.Ph
a. Housekeeping.
3. DUR Board Update...........................................................................Robyn Seely, PharmD.
4. Ophthalmic Antibiotics
Included agents: Azithromycin, Bacitracin, Bacitracin/Polymyxin B, Bacitracin/Neomycin/Polymyxin B, Bacitracin/Neomycin/Polymyxin B/Hydrocortisone, Besifloxacin, Ciprofloxacin, Erythromycin, Gatifloxacin, Gentamicin, Levofloxacin, Moxifloxacin, Natamycin, Neomycin/Polymyxin B/Gramicidin, Neomycin/Polymyxin B/Hydrocortisone, Ofloxacin, Sulfacetamide, Tobramycin, Trimethoprim/Polymyxin B
a. Over view of Clinical Outcomes…………….…………Melissa Archer, PharmD
b. Other States Report…………………………………………. Lisa V. Hunt, R.Ph.
c. Public Comment
d. Board Disscussion/Questions
e. Board Action
5. Next Meeting Information………………………………………… Lisa V. Hunt, R.Ph.
6. Meeting Adjourned………………………………….........Chair, Ellie Brownstein, M.D.
Public comment that responds to the materials presented by the College of Pharmacy at the University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the Drug Information Service and are posted in advance on the P&T Committee website.
Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:
Dr. Gary Oderda
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820
All materials must be clearly labeled that are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Utah Medicaid P&T Schedule 2012
January 2012
Ophthalmic Anti-inflammatory Drugs
Included agents: Bacitracin/Neomycin/Polymyxin B/Hydrocortisone, Bromfenac, Dexamethasone, Diclofenac, Difluprednate, Fluocinolone, Fluorometholone, Flurbiprofen, Ketorolac, Loteprednol, Neomycin/Polymyxin B/Hydrocortisone, Nepafenac, PrednisoLONE, Rimexolone, Triamcinolone
Documents: UU class review, UU list of available agents and dosage forms
February 2012
Antivirals for HSV
Included agents: Acyclovir, Famciclovir, Valacyclovir
Antivirals for Influenza
Included agents: Amantadine, Oseltamivir, Rimantadine, Zanamivir
Documents: UU class review, UU list of available agents
|
| Notice of Special Accommodations: | Lisa Hunt,801-538-6317 |
| Notice of Electronic or telephone participation: | No |
| Other information: | |
| Contact Information: |
Ngan Huynh 801-538-6155 nganhuynh@utah.gov |
| Posted on: | May 31, 2011 04:35 PM |
| Last edited on: | December 07, 2011 12:10 PM |